It will measure the efficacy and safety of Formula C for people with (PACS).
- It will measure the efficacy and safety of Formula C for people with (PACS).
- The study is a single blind, placebo-controlled trial with an open label arm.
- Participants will not know if they are receiving the Formula C which includes terpenes and cannabidiol (CBD), or the placebo during the first 28-day arm.
- Sterling\xe2\x80\x99s mandate is to ensure compliance with federal regulations to protect the rights and welfare of human participants in research studies.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210413005424/en/\n'